Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – ...
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...
VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / StimCell Energetics Inc. (OTC PINK:STME) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote anti-aging, longevity and ...
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside ...
Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced ...
Free to participants in the 2025 survey of PM software, this comprehensive report offers critical insights into trends, developments, and vendor capabilities shaping the future of practice management.
A powerful, new framework called "Annotatability" has been developed by researchers at the Hebrew University of Jerusalem to address a major challenge in biological research -- identifying mismatches ...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the generation of over $100,000 in revenue following the signing of a Binding ...
Teos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
Qure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4 ...